Anti-CTLA-4 [9D9]

Absolute Antibody

Anti-CTLA-4 [9D9]

9

The antibody has been used to block CTLA-4 and has been shown to enhance T-cell immunity against tumours (Quezada et al, 2006). 9D9 also has an anti-B16/BL6 melanoma effect in non-irradiated tumour-bearing recipients when given as combinatorial therapy with Gvax (Peggs et al, 2009). Selby et al. (PMID: 24777248) show how conversion of the original mouse IgG2b to a mouse IgG2a greatly increases anti-tumor activity of the 9D9 antibody in both MC38 (C57BL/6 mice) and CT26 (BALB/c mice) models. This mechanism both involves blockade of CTLA4 as well as depletion of tumor-infiltrating regulatory T-cells. Fc Silent antibodies were shown to have reduced anti-tumor activity as they did not deplete tumor infiltrating regulatory T-cells, however they lead to expansion of peripheral Tregs.

ImmunoFluorescence, Neutralisation/Blocking

Research Use Only

Monoclonal

9D9

Ctla4

cytotoxic T-lymphocyte-associated protein 4

Cd152; CD152 antigen; Ctla; Ctla-4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte-associated antigen 4; Ly-5; Ly-56

Mouse

IgG2a

Cytotoxic T-lymphocyte protein 4

This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques.

-20°C,2°C to 8°C

12352203